舒尼替尼2周用药1周停药方案治疗转移性肾细胞癌的II期研究
该II期研究评估舒尼替尼2周用药1周停药(2/1)方案在初治转移性肾细胞癌患者中的毒性和疗效。主要终点为≥3级疲劳、腹泻或手足综合征发生率低于15%,但实际25%患者发生≥3级毒性,未达到主要终点;然而无4级毒性,停药率低(10%),客观缓解率57%,中位无进展生存13.7个月。
要点
- 2/1方案未达到主要终点:25%患者发生≥3级疲劳、手足综合征或腹泻。
- 无4级毒性,仅10%因毒性停药,37%需减量。
- 客观缓解率57%,中位无进展生存13.7个月,中位总生存未达到。
核心结论
- 2/1方案未降低≥3级毒性至预设阈值以下,但无4级毒性、停药率低且疗效高。
研究设计与样本
- 主要终点为≥3级疲劳、腹泻或手足综合征发生率低于15%。
主要发现
- 中位随访17个月,25%患者发生≥3级疲劳、手足综合征或腹泻。
- 37%患者需减量,10%因毒性停药。
- 客观缓解率57%,中位无进展生存13.7个月,中位总生存未达到。
- 12周时FACT-G评分较基线下降0%至10%,治疗时间较长者下降较少。
关键数值与推荐
- 主要终点阈值:≥3级疲劳、腹泻或手足综合征发生率<15%。
- 实际≥3级毒性发生率25%,未达到主要终点。
临床怎么用
- 2/1方案可作为转移性肾细胞癌的替代选择,尤其关注无4级毒性和低停药率。
- 需密切监测毒性并适时调整剂量,37%患者需减量。
局限性
- 主要终点未达到,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Standard frontline treatment of patients with metastatic renal cell carcinoma currently includes sunitinib. A barrier to long-term treatment with sunitinib includes the development of significant adverse effects, including diarrhea, hand-foot syndrome (HFS), and fatigue. This trial assessed the effect of an alternate 2 weeks on, 1 week off (2/1) schedule of sunitinib on toxicity and efficacy in previously untreated patients with metastatic renal cell carcinoma. Methods Patients started with oral administration of 50 mg sunitinib on a 2/1 schedule and underwent schedule and dose alterations if toxicity developed. The primary end point was < 15% grade ≥ 3 fatigue, diarrhea, or HFS. With 60 patients, the upper bound of the CI would fall below the published 4/2 schedule grade ≥ 3 toxicity rate of 25% to 30%. Results Fifty-nine patients were treated between August 2014 and March 2016. Seventy-seven percent were intermediate or poor risk per Memorial Sloan Kettering Cancer Center criteria. With a median follow-up of 17 months, 25% of patients experienced grade 3 fatigue, HFS, or diarrhea; 37% required a dose reduction, and 10% discontinued because of toxicity. The overall response rate was 57%, median progression-free survival was 13.7 months, and median overall survival was not reached. At 12 weeks, Functional Assessment of Cancer Therapy-General scores dropped between 0% and 10% from baseline, with less reduction in patients who continued treatment longer. Conclusion The primary end point of decreased grade 3 toxicity was not met; however, treatment with a 2/1 sunitinib schedule is associated with a lack of grade 4 toxicity, a low patient discontinuation rate, and high efficacy.
引用
- Jonasch E, Slack RS, Geynisman DM, et al. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2018. PMID: 29641297. doi:10.1200/JCO.2017.77.1485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。